Register Login
Register to leave comments
  • News bot Jan. 9, 2026, 1:52 p.m.

    📋 PDS BIOTECHNOLOGY CORPORATION (PDSB) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 08:50:48

    Event Type: Clinical Trial Update

    Event Details:

    PDS Biotechnology Corporation (PDSB) Announces Clinical Trial Update PDS Biotechnology Corporation (PDSB) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: basis, step
    • Diseases/Conditions: full approval as originally recommended by FDA
    • Clinical Stage: clinical trial, Phase 3
    • Collaboration: FDA
    • Updated Timeline: December 2025

    🔬 Clinical Development Pipeline (PDS BIOTECHNOLOGY CORPORATION):

    Product Type Development Stage Therapeutic Area Source
    SLOG chemotherapy DRUG Phase PHASE1 Pancreatic Carcinoma Stage II ClinicalTrials.gov
    SLOG + Allogeneic NK cell BIOLOGICAL Phase PHASE1 Pancreatic Carcinoma Stage II ClinicalTrials.gov
    Magicell-NK contains NK cells suspended in 100 mL normal saline BIOLOGICAL Phase PHASE1 Colon Cancer Stage I ClinicalTrials.gov
    sitaxsentan sodium DRUG Phase PHASE2 Pulmonary Hypertension ClinicalTrials.gov
    Argatroban DRUG Phase PHASE4 Kidney Failure, Chronic ClinicalTrials.gov
    Spinal fusion PROCEDURE Approved Degenerative Lumbar Spondylolisthesis ClinicalTrials.gov
    Surgical implantation of OP-1 device or autograft bone graft material DEVICE Approved Tibial Nonunions ClinicalTrials.gov
    AT-301 BIOLOGICAL Phase PHASE1 Bird Flu ClinicalTrials.gov
    Use of OP-1 Putty in Uninstrumented posterolateral fusion DEVICE Approved Degenerative Lumbar Spondylolisthesis ClinicalTrials.gov
    Trafermin 0.01% spray DRUG Phase PHASE3 Diabetic Foot Ulcer of Neuropathic Origin ClinicalTrials.gov
    Antroquinonol DRUG Phase PHASE1 Non-small Cell Lung Cancer ClinicalTrials.gov
    TLIF with a PEEK Spacer System and XIA Spinal System DEVICE Approved Degenerative Disc Disease ClinicalTrials.gov
    OBP-301 BIOLOGICAL Phase PHASE1 Carcinoma, Hepatocellular ClinicalTrials.gov
    Platelet-rich plasma OTHER Approved Discogenic Pain ClinicalTrials.gov
    placebo DRUG Phase PHASE2 Hyperlipidemias ClinicalTrials.gov
    control OTHER Approved Platelet-Rich Plasma ClinicalTrials.gov
    Placebo oral capsule DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    Antroquinonol Capsule 100mg DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    Antroquinonol Capsule 50mg DRUG Phase PHASE2 Atopic Dermatitis ClinicalTrials.gov
    Transforaminal lumbar interbody fusion with local bone graft OTHER Approved Bone Marrow ClinicalTrials.gov
    Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration OTHER Approved Bone Marrow ClinicalTrials.gov
    Core decompression surgery OTHER Preclinical Avascular Necrosis of Femur ClinicalTrials.gov
    Core decompression surgery with bone marrow concentration OTHER Preclinical Avascular Necrosis of Femur ClinicalTrials.gov
    Antroquinonol capsule 200mg DRUG Phase PHASE2 Chronic Hepatitis B ClinicalTrials.gov
    arthroscopic repair OTHER Preclinical Rotator Cuff Tear ClinicalTrials.gov
    arthroscopic repair with bone marrow concentration OTHER Preclinical Rotator Cuff Tear ClinicalTrials.gov
    intramedullary nail fixation OTHER Preclinical Bone Marrow ClinicalTrials.gov
    intramedullary nail fixation with bone marrow concentration OTHER Preclinical Bone Marrow ClinicalTrials.gov
    docetaxel DRUG Phase PHASE2 Lung Cancer ClinicalTrials.gov
    PI-88 DRUG Phase PHASE2 Lung Cancer ClinicalTrials.gov
    dacarbazine or DTIC DRUG Phase PHASE2 Melanoma ClinicalTrials.gov
    PI-88 and dacarbazine DRUG Phase PHASE2 Melanoma ClinicalTrials.gov
    SC-Ad6-1 BIOLOGICAL Phase PHASE1 Covid19 ClinicalTrials.gov
    ABC294640 DRUG Phase PHASE2 Carcinoma, Hepatocellular ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: PDS Biotechnology Corporation
    • CIK: 0001472091
    • Ticker Symbol: PDSB
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories